Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.69 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293436 | 0.89 | CRHBP (0.77) | HRH4CRHBPCRHR2HRH3CYP1A2 | |
| SCHEMBL2167266 | 0.89 | HRH4 (0.89) | HRH4HRH3 | |
| SCHEMBL3634900 | 0.87 | HRH4 (0.61) | HRH4CRHBPCRHR2HRH3CYP1A2 | |
| SCHEMBL2166485 | 0.84 | HRH4 (1.00) | HRH4CRHBPCRHR2HRH3 | |
| SCHEMBL607332 | 0.83 | HRH4 (0.96) | HRH4CRHBPCRHR2HRH3 | |
| SCHEMBL605178 | 0.83 | HRH4 (0.96) | HRH4CRHBPCRHR2HRH3 | |
| SCHEMBL3177803 | 0.81 | HRH4 (0.76) | HRH4CRHBPCRHR2HRH3NPSR1 | |
| SCHEMBL10844743 | 0.81 | HRH4 (0.76) | HRH4CRHBPCRHR2HRH3NPSR1 | |
| SCHEMBL13929505 | 0.81 | HRH4 (0.68) | HRH4CRHBPCRHR2HRH3NPSR1 | |
| SCHEMBL2168885 | 0.81 | HRH4 (0.75) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008060766-A2 | HISTAMINE H4 RECEPTOR LIGANDS FOR USE IN PAIN TREATMENT | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885CRHBP 523/4885CRHR2 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.